Compare W W Grainger Inc (GWW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs BIO-TECHNE Corp — how do they compare? W W Grainger Inc trades at $1,300.82 (market cap $61.11B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: W W Grainger Inc is far larger — about 5.4× BIO-TECHNE Corp's market cap, and W W Grainger Inc pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| GWW | TECH | |
|---|---|---|
Market Cap | $61.11B | $11.24B |
Sector | Technology | Health |
52-Week High | $1.40K | $72.29 |
52-Week Low | $918.18 | $43.31 |
Enterprise Value | $63.32B | $11.32B |
Dividend Yield | 0.77% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,277.55, down 0.39% on the day, amid a bearish technical signal. The stock has shown strong fundamental performance with Q2 2026 EPS beating estimates at $12.01 and revenue growth to $5.0 billion, leading to a raised full-year outlook. Analyst consensus is a Buy with a $1,310 price target, though technical indicators suggest near-term pressure with support at $1,270 and resistance at $1,290.
The outlook for GWW is positive based on earnings momentum and margin expansion, but risks include macroeconomic sensitivity and competitive pressures. The stock's high P/E of 33.07 indicates premium valuation, requiring sustained growth to justify current levels. Institutional sentiment remains cautious with a Hold-heavy rating distribution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
